Skip to main content
Erschienen in: Heart and Vessels 3/2018

30.09.2017 | Original Article

Chronic phase improvements in electrocardiographic and echocardiographic manifestations of left ventricular hypertrophy after alcohol septal ablation for drug-refractory hypertrophic obstructive cardiomyopathy

verfasst von: Junya Matsuda, Mitsunobu Kitamura, Morimasa Takayama, Yoichi Imori, Junsuke Shibuya, Yoshiaki Kubota, Hideto Sangen, Shunichi Nakamura, Hitoshi Takano, Kuniya Asai, Wataru Shimizu

Erschienen in: Heart and Vessels | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

After alcohol septal ablation (ASA), regression of left ventricular hypertrophy (LVH) has been observed in several studies using echocardiography or cardiac magnetic resonance, and favorable changes of myocardial excitation have been expected. However, no studies have focused on the alteration of electrocardiography (ECG) findings after ASA. Therefore, we evaluated serial changes in ECG parameters during the chronic phase after ASA for drug-refractory hypertrophic obstructive cardiomyopathy (HOCM). From 1998 to 2014, we performed 187 ASA procedures in 157 drug-refractory HOCM patients. After excluding patients who underwent dual-chamber pacing therapy and who underwent staged or repeat ASA within 2 years after the index ASA, 25 patients without bundle branch block and additional pacemaker implantation were enrolled in the main study group. ECGs, echocardiograms, and clinical follow-up data were evaluated at baseline and, 1, 6, 12, and 24 months after ASA. Patients with bundle branch block or additional pacemaker implantation were assigned in a referential group (n = 79), in which the echocardiographic changes between baseline and at 1 year were evaluated. Sokolow–Lyon index (SLi), Cornell index, and total 12-lead QRS amplitude significantly decreased during 2-year follow-up after ASA. SLi and Cornell index significantly decreased from 6 to 12 months (p < 0.05 vs. p < 0.01). Changes in SLi were significantly associated with changes in the interventricular septal thickness (r = 0.54, p < 0.005), left ventricular mass index (r = 0.40, p = 0.050), and peak creatine phosphokinase level (r = −0.41, p = 0.042), but not in the Cornell index and 12-lead QRS amplitude. In the comparison between baseline and at 1 year, significant improvements in the interventricular septal thickness, posterior wall thickness, left atrial size, E/A ratio, and E/e′ were observed in the echocardiographic study. Changes of SLi reflected regression of LVH after ASA with the best correlation. During the chronic phase after ASA, LVH regression was confirmed by echocardiographic and ECG parameters.
Literatur
1.
Zurück zum Zitat Amano Y, Takayama M, Kumita S, Kumazaki T (2007) MR imaging evaluation of regional, remote, and global effects of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy. J Comput Assist Tomogr 31:600–604CrossRefPubMed Amano Y, Takayama M, Kumita S, Kumazaki T (2007) MR imaging evaluation of regional, remote, and global effects of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy. J Comput Assist Tomogr 31:600–604CrossRefPubMed
2.
Zurück zum Zitat van Dockum WG, Beek AM, ten Cate FJ, ten Berg JM, Bondarenko O, Gotte MJ, Twisk JW, Hofman MB, Visser CA, van Rossum AC (2005) Early onset and progression of left ventricular remodeling after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Circulation 111:2503–2508CrossRefPubMed van Dockum WG, Beek AM, ten Cate FJ, ten Berg JM, Bondarenko O, Gotte MJ, Twisk JW, Hofman MB, Visser CA, van Rossum AC (2005) Early onset and progression of left ventricular remodeling after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Circulation 111:2503–2508CrossRefPubMed
3.
Zurück zum Zitat Mazur W, Nagueh SF, Lakkis NM, Middleton KJ, Killip D, Roberts R, Spencer WH 3rd (2001) Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 103:1492–1496CrossRefPubMed Mazur W, Nagueh SF, Lakkis NM, Middleton KJ, Killip D, Roberts R, Spencer WH 3rd (2001) Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 103:1492–1496CrossRefPubMed
4.
Zurück zum Zitat Guo H, Wang P, Xing Y, Peng F, Jiang J, Yang B, You B, Qiu Y, Lee JD (2007) Delayed electrocardiographic changes after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy. J Electrocardiol 40(356):e1–e6 Guo H, Wang P, Xing Y, Peng F, Jiang J, Yang B, You B, Qiu Y, Lee JD (2007) Delayed electrocardiographic changes after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy. J Electrocardiol 40(356):e1–e6
5.
Zurück zum Zitat Kazmierczak J, Kornacewicz-Jach Z, Kisly M, Gil R, Wojtarowicz A (1998) Electrocardiographic changes after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Heart 80:257–262CrossRefPubMedPubMedCentral Kazmierczak J, Kornacewicz-Jach Z, Kisly M, Gil R, Wojtarowicz A (1998) Electrocardiographic changes after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Heart 80:257–262CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Ostman-Smith I, Wisten A, Nylander E, Bratt EL, Granelli A, Oulhaj A, Ljungstrom E (2010) Electrocardiographic amplitudes: a new risk factor for sudden death in hypertrophic cardiomyopathy. Eur Heart J 31:439–449CrossRefPubMed Ostman-Smith I, Wisten A, Nylander E, Bratt EL, Granelli A, Oulhaj A, Ljungstrom E (2010) Electrocardiographic amplitudes: a new risk factor for sudden death in hypertrophic cardiomyopathy. Eur Heart J 31:439–449CrossRefPubMed
7.
Zurück zum Zitat Bongioanni S, Bianchi F, Migliardi A, Gnavi R, Pron PG, Casetta M, Conte MR (2007) Relation of QRS duration to mortality in a community-based cohort with hypertrophic cardiomyopathy. Am J Cardiol 100:503–506CrossRefPubMed Bongioanni S, Bianchi F, Migliardi A, Gnavi R, Pron PG, Casetta M, Conte MR (2007) Relation of QRS duration to mortality in a community-based cohort with hypertrophic cardiomyopathy. Am J Cardiol 100:503–506CrossRefPubMed
8.
Zurück zum Zitat Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW (2011) 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 58:e212–e260CrossRefPubMed Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW (2011) 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 58:e212–e260CrossRefPubMed
9.
Zurück zum Zitat Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440–1463CrossRefPubMed Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440–1463CrossRefPubMed
10.
Zurück zum Zitat Dollar AL, Roberts WC (1989) Usefulness of total 12-lead QRS voltage compared with other criteria for determining left ventricular hypertrophy in hypertrophic cardiomyopathy: analysis of 57 patients studied at necropsy. Am J Med 87:377–381CrossRefPubMed Dollar AL, Roberts WC (1989) Usefulness of total 12-lead QRS voltage compared with other criteria for determining left ventricular hypertrophy in hypertrophic cardiomyopathy: analysis of 57 patients studied at necropsy. Am J Med 87:377–381CrossRefPubMed
11.
Zurück zum Zitat Okin PM, Devereux RB, Nieminen MS, Jern S, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Julius S, Dahlof B (2001) Relationship of the electrocardiographic strain pattern to left ventricular structure and function in hypertensive patients: the LIFE study. Losartan Intervention For End point. J Am Coll Cardiol 38:514–520CrossRefPubMed Okin PM, Devereux RB, Nieminen MS, Jern S, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Julius S, Dahlof B (2001) Relationship of the electrocardiographic strain pattern to left ventricular structure and function in hypertensive patients: the LIFE study. Losartan Intervention For End point. J Am Coll Cardiol 38:514–520CrossRefPubMed
12.
Zurück zum Zitat Waszyrowski T, Kasprzak JD, Krzeminska-Pakula M, Drozdz J, Dziatkowiak A, Zaslonka J (1996) Regression of left ventricular dilatation and hypertrophy after aortic valve replacement. Int J Cardiol 57:217–225CrossRefPubMed Waszyrowski T, Kasprzak JD, Krzeminska-Pakula M, Drozdz J, Dziatkowiak A, Zaslonka J (1996) Regression of left ventricular dilatation and hypertrophy after aortic valve replacement. Int J Cardiol 57:217–225CrossRefPubMed
13.
Zurück zum Zitat van Dockum WG, ten Cate FJ, ten Berg JM, Beek AM, Twisk JW, Vos J, Hofman MB, Visser CA, Van Rossum AC (2004) Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: evaluation by contrast-enhanced magnetic resonance imaging. J Am Coll Cardiol 43:27–34CrossRefPubMed van Dockum WG, ten Cate FJ, ten Berg JM, Beek AM, Twisk JW, Vos J, Hofman MB, Visser CA, Van Rossum AC (2004) Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: evaluation by contrast-enhanced magnetic resonance imaging. J Am Coll Cardiol 43:27–34CrossRefPubMed
14.
Zurück zum Zitat Biagini E, Pazzi C, Olivotto I, Musumeci B, Limongelli G, Boriani G, Pacileo G, Mastromarino V, Bacchi Reggiani ML, Lorenzini M, Lai F, Berardini A, Mingardi F, Rosmini S, Resciniti E, Borghi C, Autore C, Cecchi F, Rapezzi C (2016) Usefulness of electrocardiographic patterns at presentation to predict long-term risk of cardiac death in patients with hypertrophic cardiomyopathy. Am J Cardiol 118:432–439CrossRefPubMed Biagini E, Pazzi C, Olivotto I, Musumeci B, Limongelli G, Boriani G, Pacileo G, Mastromarino V, Bacchi Reggiani ML, Lorenzini M, Lai F, Berardini A, Mingardi F, Rosmini S, Resciniti E, Borghi C, Autore C, Cecchi F, Rapezzi C (2016) Usefulness of electrocardiographic patterns at presentation to predict long-term risk of cardiac death in patients with hypertrophic cardiomyopathy. Am J Cardiol 118:432–439CrossRefPubMed
15.
Zurück zum Zitat Maron BJ, Wolfson JK, Ciro E, Spirito P (1983) Relation of electrocardiographic abnormalities and patterns of left ventricular hypertrophy identified by 2-dimensional echocardiography in patients with hypertrophic cardiomyopathy. Am J Cardiol 51:189–194CrossRefPubMed Maron BJ, Wolfson JK, Ciro E, Spirito P (1983) Relation of electrocardiographic abnormalities and patterns of left ventricular hypertrophy identified by 2-dimensional echocardiography in patients with hypertrophic cardiomyopathy. Am J Cardiol 51:189–194CrossRefPubMed
16.
Zurück zum Zitat Gwathmey JK, Warren SE, Briggs GM, Copelas L, Feldman MD, Phillips PJ, Callahan M Jr, Schoen FJ, Grossman W, Morgan JP (1991) Diastolic dysfunction in hypertrophic cardiomyopathy. Effect on active force generation during systole. J Clin Invest 87:1023–1031CrossRefPubMedPubMedCentral Gwathmey JK, Warren SE, Briggs GM, Copelas L, Feldman MD, Phillips PJ, Callahan M Jr, Schoen FJ, Grossman W, Morgan JP (1991) Diastolic dysfunction in hypertrophic cardiomyopathy. Effect on active force generation during systole. J Clin Invest 87:1023–1031CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Palmiter KA, Solaro RJ (1997) Molecular mechanisms regulating the myofilament response to Ca2 + : implications of mutations causal for familial hypertrophic cardiomyopathy. Basic Res Cardiol 92(Suppl 1):63–74CrossRefPubMed Palmiter KA, Solaro RJ (1997) Molecular mechanisms regulating the myofilament response to Ca2 + : implications of mutations causal for familial hypertrophic cardiomyopathy. Basic Res Cardiol 92(Suppl 1):63–74CrossRefPubMed
18.
Zurück zum Zitat Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN (1998) A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93:215–228CrossRefPubMedPubMedCentral Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN (1998) A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93:215–228CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Hamada M, Ikeda S, Shigematsu Y (2014) Advances in medical treatment of hypertrophic cardiomyopathy. J Cardiol 64:1–10CrossRefPubMed Hamada M, Ikeda S, Shigematsu Y (2014) Advances in medical treatment of hypertrophic cardiomyopathy. J Cardiol 64:1–10CrossRefPubMed
20.
Zurück zum Zitat Abergel E, Tase M, Menard J, Chatellier G (1996) Influence of obesity on the diagnostic value of electrocardiographic criteria for detecting left ventricular hypertrophy. Am J Cardiol 77:739–744CrossRefPubMed Abergel E, Tase M, Menard J, Chatellier G (1996) Influence of obesity on the diagnostic value of electrocardiographic criteria for detecting left ventricular hypertrophy. Am J Cardiol 77:739–744CrossRefPubMed
21.
Zurück zum Zitat Levy D, Labib SB, Anderson KM, Christiansen JC, Kannel WB, Castelli WP (1990) Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. Circulation 81:815–820CrossRefPubMed Levy D, Labib SB, Anderson KM, Christiansen JC, Kannel WB, Castelli WP (1990) Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. Circulation 81:815–820CrossRefPubMed
22.
Zurück zum Zitat Carlsson MB, Tragardh E, Engblom H, Hedstrom E, Wagner G, Pahlm O, Arheden H (2006) Left ventricular mass by 12-lead electrocardiogram in healthy subjects: comparison to cardiac magnetic resonance imaging. J Electrocardiol 39:67–72CrossRefPubMed Carlsson MB, Tragardh E, Engblom H, Hedstrom E, Wagner G, Pahlm O, Arheden H (2006) Left ventricular mass by 12-lead electrocardiogram in healthy subjects: comparison to cardiac magnetic resonance imaging. J Electrocardiol 39:67–72CrossRefPubMed
Metadaten
Titel
Chronic phase improvements in electrocardiographic and echocardiographic manifestations of left ventricular hypertrophy after alcohol septal ablation for drug-refractory hypertrophic obstructive cardiomyopathy
verfasst von
Junya Matsuda
Mitsunobu Kitamura
Morimasa Takayama
Yoichi Imori
Junsuke Shibuya
Yoshiaki Kubota
Hideto Sangen
Shunichi Nakamura
Hitoshi Takano
Kuniya Asai
Wataru Shimizu
Publikationsdatum
30.09.2017
Verlag
Springer Japan
Erschienen in
Heart and Vessels / Ausgabe 3/2018
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-017-1053-9

Weitere Artikel der Ausgabe 3/2018

Heart and Vessels 3/2018 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.